Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference
September 12 2012 - 2:00AM
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced
today that Dr. David Aviezer, the Company's President and Chief
Executive Officer, will present at the UBS Global Life Sciences
Conference on Thursday, September 20, 2012 at 8:00 AM ET at the
Grand Hyatt Hotel in New York City. A live webcast of the
presentation will be available at www.protalix.com on the event
calendar page. A replay will be archived and available after the
conclusion of the presentation for 30 days.
About Protalix
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell based
expression system, ProCellEx(R). Protalix's unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner. Protalix's
first approved product manufactured by ProCellEx, ELELYSO™
(taliglucerase alfa), was approved for marketing by the U.S. Food
and Drug Administration on May 1, 2012 and is partnered with Pfizer
for worldwide development and commercialization, excluding Israel,
where Protalix retains full rights. Marketing applications for
taliglucerase alfa have been filed in Europe, Israel, Brazil and
Australia. Protalix's development pipeline also includes the
following product candidates: PRX-102, a modified version of the
recombinant human alpha-GAL-A protein for the treatment of Fabry
disease; PRX-105, a pegylated recombinant human
acetylcholinesterase in development for several therapeutic and
prophylactic indications, a biodefense program and an
organophosphate-based pesticide treatment program; an
orally-delivered glucocerebrosidase enzyme that is naturally
encased in carrot cells, also for the treatment of Gaucher disease;
pr-antiTNF, a similar plant cell version of etanercept (Enbrel(R))
for the treatment of certain immune diseases such as rheumatoid
arthritis, juvenile idiopathic arthritis, ankylosing spondylitis,
psoriatic arthritis and plaque psoriasis; and others.
Forward Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. The terms
"anticipate," "believe," "estimate," "expect," "plan" and "intend"
and other words or phrases of similar import are intended to
identify forward-looking statements. These forward-looking
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. The statements in this
release are valid only as of the date hereof and we disclaim any
obligation to update this information.
CONTACT: Investor Contact
Tricia Swanson
The Trout Group, LLC
646-378-2953
tswanson@troutgroup.com
Media Contact
Jennifer Conrad or Kari Watson
MacDougall Biomedical Communications
781-235-3060
jconrad@macbiocom.com
kwatson@macbiocom.com